BIOGEN INC

Biogen’s latest slide shows investors losing faith—$250.69 stock, near 52‑week high, yet a weak 200‑day SMA signals stalled innovation and the need for clinical breakthroughs.

Biogen’s stock climbs 5% after beating earnings and raising FY guidance, fueled by strong EMPAVELI results and bullish analyst upgrades.

Biogen’s latest market update shows a 10.97% rise and a $243.10 close, positioning it as a top healthcare performer with strong sector momentum and peer gains.